Randeep Sangha

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

Robert Marcus, Andrew Davies, Kiyoshi Ando et al. · New England Journal of Medicine · 2017 · 788 citations · Full text

Medicine, Immunology, Oncology +14

The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas Adenocarcinoma

Jennifer L. Spratlin, Randeep Sangha, Darryl Glubrecht et al. · Clinical Cancer Research · 2004 · 425 citations

Medicine, Oncology, Pharmacology +13

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227

Julie R. Brahmer, Jong-Seok Lee, Tudor–Eliade Ciuleanu et al. · Journal of Clinical Oncology · 2022 · 381 citations · Full text

Medicine, Oncology, Pharmacology +17

Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study

Maria Corinna Palanca-Wessels, Myron S. Czuczman, Gilles Salles et al. · The Lancet Oncology · 2015 · 335 citations

Pharmacy, Immunology, Oncology +16

EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

Jonathan E. Rosenberg, Srikala S. Sridhar, Jingsong Zhang et al. · Journal of Clinical Oncology · 2020 · 327 citations · Full text

Medicine, Oncology, Pharmacology +17